Keros Therapeutics (KROS) Total Liabilities (2019 - 2025)

Keros Therapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $34.9 million for Q4 2025.

• Quarterly Total Liabilities fell 21.3% year-over-year to $34.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $34.9 million (down 21.3% YoY) and the FY2025 annual result came in at $34.9 million, down 21.3% from the prior year.
• Total Liabilities was $34.9 million for Q4 2025 at Keros Therapeutics, down from $39.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $55.7 million in Q1 2025 and bottomed at $7.8 million in Q2 2021.
• A 5-year average of $28.7 million and a median of $30.2 million in 2023 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2023 — Total Liabilities soared 163.82% — and 2025, when it decreased 21.3%.
• Keros Therapeutics' Total Liabilities stood at $12.1 million in 2021, then jumped by 143.09% to $29.4 million in 2022, then climbed by 28.8% to $37.8 million in 2023, then gained by 17.25% to $44.3 million in 2024, then dropped by 21.3% to $34.9 million in 2025.
• Business Quant data shows KROS's Total Liabilities at $34.9 million in Q4 2025, $39.2 million in Q3 2025, and $50.4 million in Q2 2025.